Skip to content
Medical Health Aged Care, Science

New genetic tool predicts risk of liver disease in heavy drinkers

Centenary Institute 2 mins read

An international research group led by the Centenary Institute has developed a new genetic risk prediction tool to identify heavy drinkers most at risk of developing alcohol-associated cirrhosis, a severe form of liver disease.  

 

Reported in the journal Hepatology Communications, the tool offers new hope for the early detection and prevention of alcohol-associated cirrhosis, a condition responsible for over 300,000 global deaths annually.

 

While excessive alcohol consumption is known to cause liver damage, not all heavy drinkers develop cirrhosis, which is characterised by scarring of the liver. The newly developed tool, known as a polygenic risk score (PRS), helps pinpoint individuals most likely to suffer from alcohol-associated cirrhosis based on their genetic makeup.

 

In developing the PRS, the researchers compared the genetic profiles of thousands of patients with alcohol-associated cirrhosis to those of heavy drinkers without liver damage. Analysing millions of genetic variations, a risk score was derived from 20 specific genetic markers.

 

Clinical Professor Devanshi Seth, the senior author of the study and researcher at both the Centenary Institute’s Centre for Healthy Ageing and Drug Health Services, Sydney Local Health District, said the PRS was extremely effective.

 

"Our polygenic risk score is a powerful new approach to predicting alcohol-associated cirrhosis through an individual’s genes. It allows us to identify individuals at high risk, enabling earlier intervention and preventive measures to help stop liver disease before it progresses,” said Clinical Professor Seth.

 

The study also revealed that the PRS significantly improves the prediction of alcohol-associated cirrhosis when combined with other traditional (non-genetic) risk factors such as drinking habits, age, body mass index (BMI) and diabetes status. Further, the tool has been found to be useful in predicting the risk of other liver diseases related to metabolic (non-alcoholic) factors.

 

"Our tool not only predicts the risk of alcohol-associated cirrhosis but has also demonstrated its utility in identifying risks for other liver diseases such as fatty liver disease, suggesting that shared genetic factors are involved,” said Clinical Professor Seth.

 

“Moreover, individuals who learn that they are at higher risk through this tool may be motivated to adopt healthier lifestyles to help prevent the progression of disease,” she added. 

 

“This tool can aid in the early detection and prevention of multiple liver conditions, offering a far more comprehensive approach to liver health."

 

The research was undertaken by the multi-national GenomALC Consortium led by Clinical Professor Seth and funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) a part of the National Institutes of Health (NIH), USA.

 

[ENDS]

 

Publication:

A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry.

https://journals.lww.com/hepcomm/fulltext/2024/06010/a_polygenic_risk_score_for_alcohol_associated.2.aspx

 

 


Key Facts:

Publication:

A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry.

https://journals.lww.com/hepcomm/fulltext/2024/06010/a_polygenic_risk_score_for_alcohol_associated.2.aspx


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.

 For more information about the Centenary Institute, visit centenary.org.au

 


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 12/04/2026
  • 07:10
Energy Enhancement System

Court Rules Against Jason Shurka in EESystem Case; $54,034 in Federal Sanctions Ordered

Clark County judge finds defendant’s public statements were not made in good faith. The ruling caps months of legal proceedings brought by the inventor…

  • Contains:
  • Medical Health Aged Care
  • 12/04/2026
  • 06:25
Royal Australian College of GPs

Cleanbill report shows bulk billing rises where funding is strongest, not where competition is greatest

The Royal Australian College of General Practitioners (RACGP) says new Cleanbill data indicates what GPs have consistently warned is true: bulk billing increases where funding better reflects the true cost of care, not where there is greater competition between practices. The Cleanbill report, released today, breaks down bulk billing and gap fees by how rural a practice is based on Modified Monash Model (MM1–7) classification. It shows that the largest increases in 100% bulk billing have occurred in regional and rural areas where government incentives are highest, yet where health department data show there are fewer GPs per person. RACGP…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 10/04/2026
  • 11:12
Aravax

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifyingimmunotherapies for food allergy, today announces two additions to its Board of Directors, former CEO of ALK-Abello A/S, Carsten Hellmann and former Chief Commercial Officer of Aimmune Therapeutics, Andrew Oxtoby. Collectively, Carsten and Andrew bring to Aravax exceptionally deep experience from the pharmaceutical industry and, specifically, the allergy therapeutics field. Andrew has deep pharmaceutical industry expertise spanning development, product launch, fundraising and exits from working with large and small companies in the U.S. and Europe. As Chief Commercial Officer he built the global commercial organisation for the approval and launch in the US…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.